Beam Therapeutics Inc. · Biotechnology
BEAMBeam Therapeutics Inc.
No earnings date on file for this stock yet.
Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →
Beam Therapeutics earnings preview: what the record says
Across its last 8 reports, BEAM beat the EPS consensus 3 times out of 8 with a figure on file, and the stock moved an average of 4.8% on the first trading day, closing higher 3 of 8 times. That first-day move was larger than the options-implied move in 1 of 6 reports. Measured over five sessions, the average move was 11.3%.
Historically, BEAM has usually stayed inside its implied move. NextPick tracks BEAM in its Cell / Gene Therapy basket alongside CRSP, VCEL, NTLA and PRME, whose prints read through to this one.
Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.
BEAM earnings: key questions
How much does BEAM stock move after earnings?
Over its last 8 reports, BEAM moved an average of 4.8% on the first trading day after earnings. The move was larger than the options-implied move in 1 of 6 reports.
Does BEAM usually beat earnings estimates?
BEAM beat the EPS consensus in 3 of its last 8 reports with a surprise on file and missed in 5.